Skip to main content
Premium Trial:

Request an Annual Quote

Cell Biosciences Acquires Sample Prep Firm Protein Forest

NEW YORK (GenomeWeb News) – Cell Biosciences said today that it has acquired sample-prep company Protein Forest in an all-stock transaction worth an undisclosed amount.

In addition, Cell Biosciences said that in connection with the acquisition, it has raised an additional $4 million in equity financing, led by Novo A/S.

The acquisition adds Protein Forest's digital ProteomeChip product, including instrumentation, software, reagents, and consumables, to Santa Clara, Calif.-based Cell Biosciences' portfolio of protein-analysis products.

Founded in 2002, Protein Forest, based in Lexington, Mass., developed ProteomeChip to rapidly and reproducibly fractionate proteins in complex biological samples as a prerequisite for quantitative proteomics measurements.

The technology can also be used as a sample preparation front end for other protein-analysis techniques, including Western blot analysis, mass spectrometry, and Cell Biosciences' nanoproteomic platforms.

"The lack of reproducible sample preparation has become a serious problem for proteomics researchers," Cell Biosciences President and CEO Tim Harkness said in a statement. "We believe that the digital ProteomeChip products represent a powerful solution for this market need."

In October, Cell Biosciences acquired Alpha Innotech for approximately $17.9 million. The deal, first announced in September, was intended to integrate Alpha Innotech's digital imaging systems with Cell Biosciences' CB1000 system, a nanofluidic immunoassay platform for detecting and characterizing oncoproteins and other signaling proteins in ultra-small biological samples.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.